The WD Rx Access program helps make it easier for patients who are prescribed SYPRINE® to have affordable access to the medication they need with:
For patients facing financial challenges in filling their SYPRINE® prescription, Valeant Pharmaceuticals has a Patient Assistance Program (PAP). PAP is subject to eligibility requirements.† Documents needed to determine eligibility are listed on the Enrollment Form.
WD Rx Access is sponsored by Valeant Pharmaceuticals North America LLC.
©2018 Valeant Pharmaceuticals North America LLC. All Rights Reserved. SYP.0017.USA.18
Syprine® (trientine hydrochloride) is indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine. Clinical experience with Syprine is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. Syprine and penicillamine cannot be considered interchangeable. Syprine should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.
Unlike penicillamine, Syprine is not recommended in cystinuria or rheumatoid arthritis. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, Syprine was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment.
Syprine is not indicated for treatment of biliary cirrhosis.